20/20 Biolabs, Inc. Common Stock (AIDX)vsJohnson & Johnson (JNJ)
AIDX
20/20 Biolabs, Inc. Common Stock
$0.61
-7.75%
HEALTHCARE · Cap: $6.97M
JNJ
Johnson & Johnson
$253.85
+0.00%
HEALTHCARE · Cap: $613.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 5223622% more annual revenue ($96.36B vs $1.84M). JNJ leads profitability with a 21.8% profit margin vs -279.1%. JNJ earns a higher WallStSmart Score of 57/100 (C).
AIDX
Avoid21
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
-87.1%
Fair Value
$136.12
Current Price
$253.85
$117.73 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -354.6% — below average capital efficiency
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
The strongest argument for AIDX centers on Debt/Equity, Price/Book.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AIDX profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.26 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 21/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is an innovative biotechnology firm committed to revolutionizing genomic research and diagnostics through its advanced laboratory services. With a keen focus on enhancing the accuracy and efficiency of genetic testing for clinical and research purposes, the company is poised to be a leader in the molecular diagnostics landscape. By leveraging state-of-the-art technologies, 20/20 Biolabs is strategically positioned to capitalize on the growing demand for personalized medicine and genomic data. Its strong market presence and forward-thinking initiatives underscore a compelling growth outlook within the rapidly evolving biotechnology sector.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?